

# **An ancient fecundability-associated polymorphism switches a repressor into an enhancer of endometrial *TAP2* expression**

Katelyn M. Mika<sup>1</sup> and Vincent J. Lynch<sup>1\*</sup>

<sup>1</sup>Department of Human Genetics, The University of Chicago, 920 E. 58th Street, CLSC 319C, Chicago, IL 60637, USA.

\*Correspondence: [vjlynch@uchicago.edu](mailto:vjlynch@uchicago.edu)

## Abstract

Variation in female reproductive traits such as fertility, fecundity, and fecundability are heritable in humans, but identifying and functionally characterizing genetic variants associated with these traits has been challenging. Here we explore the functional significance and evolutionary history of a C/T polymorphism of SNP rs2071473, which we have previously shown is an eQTL for *TAP2* and significantly associated with fecundability (time to pregnancy). We replicated the association between rs2071473 genotype and *TAP2* expression using GTEx data and demonstrate that *TAP2* is expressed by decidual stromal cells at the maternal-fetal interface. Next, we show that rs2071473 is located within a progesterone responsive cis-regulatory element that functions as a repressor with the T allele and an enhancer with the C allele. Remarkably, we found this polymorphism arose before the divergence of modern and archaic humans, is segregating at intermediate to high frequencies across human populations, and has genetic signatures of long-term balancing selection. This variant has also previously been identified in GWA studies of immune related disease, suggesting both alleles are maintained due to antagonistic pleiotropy.

## Author Summary

Female reproductive traits such as fertility and the time it takes to become pregnant are heritable. Many factors, including widespread contraceptive use and environmental influences, make identifying the genetic differences between individuals that are responsible for fertility differences between women difficult. We previously identified a common single nucleotide polymorphism that affects the expression of the gene *TAP2* and is significantly associated with how long it takes woman to become pregnant. Here we show that *TAP2* is expressed at the maternal-fetal interface in the uterus during pregnancy. We then show that the T version of the polymorphism functions to repress *TAP2* expression whereas the C form enhances *TAP2* expression. Remarkably, the C variant arose before the divergence of Neanderthals and modern humans and has become common in all human populations. This derived variant has previously associated with immune related diseases, suggesting the ancestral T and derived C variants are being maintained because they affect multiple traits.

## Introduction

Variation in female reproductive traits, such as age of menarche and menopause, fertility, age at first and last birth, fecundity, and fecundability are heritable in humans [1,2]. However, identifying the genetic bases for variation in most of these traits has proven challenging because of limited sample sizes, strong gene-environment interactions [1-3], widespread contraceptive use, and significant clinical heterogeneity among infertile couples. For example, while genome-wide association studies (GWAS) have identified loci associated with age of menarche and menopause [4-9], and age at first and last birth [10], few studies have successfully identified genetic variants associated with fertility, fecundity, and fecundability [3,10-12].

We recently performed an integrated expression quantitative trait locus (eQTL) mapping and association study to identify eQTLs in mid-secretory endometrium that influence pregnancy outcomes in a prospective study of Hutterite women [13-15]. Among the 189 eQTLs we identified, two were also associated with fecundability (time to pregnancy) [15]. The most significant association was rs2071473 ( $P = 1.3 \times 10^{-4}$ ), an eQTL associated with expression of *TAP2* in the HLA class II region. The C allele of rs2071473 was associated with longer intervals to pregnancy and higher expression of *TAP2* gene in mid-secretory phase (receptive) endometrium. The median time to pregnancy, for example, was 2.0, 3.1, and 4.0 months among women with the TT, CT, and CC genotypes, respectively [15].

An essential step in implantation is the establishment of receptivity by the hormone-primed endometrium. This 'window of implantation' occurs in the mid-secretory phase of the menstrual cycle [16], after endometrial stromal fibroblasts (ESFs) have differentiated (decidualized) into decidual stromal cells (DSCs) in response to progesterone and cyclic-AMP (cAMP) [17,18]. Decidualization underlies a suite of molecular, cellular, and physiological responses that support pregnancy including maternal immunotolerance of the fetal allograft [18,19]. Although function of *TAP2* in the decidualized endometrium and the process of implantation have not been elucidated, *TAP2* plays an integral role in translocating peptides from the cytosol to MHC class I molecules in the endoplasmic reticulum [20]. These data suggest that *TAP2*-dependent antigen processing and presentation by DSCs plays a role in establishing receptivity to implantation and immunotolerance at the maternal-fetal interface,

likely by modifying the interactions between DSCs and immune cells in the decidualized endometrium [21].

Here we explore the functional significance and evolutionary history of the rs2071473 C/T polymorphism. We first replicate the association between rs2071473 genotype and *TAP2* expression using GTEx data and demonstrate that *TAP2* is expressed by DSCs at the maternal-fetal interface. Next, we show that rs2071473 is located within a cAMP/progesterone responsive regulatory element and disrupts a putative DDIT3 (CHOP10) binding site that functions as a repressor with the rs2071473 T allele and an enhancer with the C allele. Remarkably, we found that the C/T polymorphism arose before the divergence of modern and archaic humans, is segregating at intermediate to high frequencies across human populations, and has genetic signatures of long-term balancing selection.

## Methods

### rs2071473 is a multi-tissue eQTL for *TAP2*, *HLA-DOB*, and *HLA-DRB6*

We replicated the association between the T/C polymorphism at rs2071473 and *TAP2* expression levels using GTEx Analysis Release V6 (dbGaP Accession phs000424.v6.p1) data for 35 tissues including the uterus [22,23]. We also used GTEx data to identify other genes for which rs2071473 was an eQTL. Briefly, we queried the GTEx database using the ‘Single tissue eQTLs search form’ for SNP rs2071473 (<http://www.gtexportal.org/home/eqtls/bySnp>).

### *TAP2* is expressed by decidual stromal cells at the maternal-fetal interface

To determine the cell-type localization of *TAP2* in the endometrium, we used data from the Human Protein Atlas immunohistochemistry collection ([www.proteinatlas.org](http://www.proteinatlas.org)) [24] for endometrium, placenta, and decidua. We examined the expression of *TAP2* in the endometrium across the menstrual cycle [25], in mid-secretory phase endometrial biopsies from women not taking hormonal contraceptives (n=11), and women using either the progestin-based contraceptives depot medroxyprogesterone acetate (DMPA) or levonorgestrel intrauterine system (LNG-IUS) for at least 6 months [26], and in DSCs treated with a PGR-specific siRNA or a non-targeted siRNA [27] using previously generated microarray expression data. These microarray datasets were analyzed with the GEO2R analysis package (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>), which implements the GEOquery [28] and limma R packages [29,30] from the Bioconductor project to quantify differential gene expression. We also

examined *TAP2* expression in RNA-Seq data previously generated from ESFs treated with control media or differentiated (decidualized) with cAMP/MPA into DSCs [31,32].

## **Cell culture and luciferase assays**

### **Cell culture**

Endometrial stromal fibroblasts (ATCC CRL-4003) immortalized with telomerase were maintained in phenol red free DMEM (Gibco) supplemented with 10% charcoal stripped fetal bovine serum (CSFBS; Gibco), 1x ITS (Gibco), 1% sodium pyruvate (Gibco), and 1% L-glutamine (Gibco). Decidualization was induced using DMEM with phenol red (Gibco), 2% CSFBS (Gibco), 1% sodium pyruvate (Gibco), 0.5mM 8-Br-cAMP (Sigma), and 1 $\mu$ M medroxyprogesterone acetate (Sigma).

### **Plasmid Transfection and Luciferase Assays**

A 1000bp region spanning 50bp upstream of rs2071732 to the 3'-end of the PGR ChIP-Seq peak was cloned into the pGL3-Basic luciferase vector (Promega), once with the T allele and once with the C allele (Genscript). A pGL3-Basic plasmid without the 1kb rs2071473 insert was used as a negative expression control. DDIT3 and PGR expression plasmids were also obtained from Genscript. Confluent ESFs in 96 well plates in 80 $\mu$ l of Opti-MEM (Gibco) were transfected with 100ng of the luciferase plasmid, 100ng of DDIT3 and/or PGR as needed, and 10ng of pRL-null with 0.1 $\mu$ l PLUS reagent (Invitrogen) and 0.25 $\mu$ l of Lipofectamine LTX (Invitrogen) in 20 $\mu$ l Opti-MEM. The cells incubated in the transfection mixture for 6hrs and the media was replaced with the phenol red free maintenance media overnight. Decidualization was then induced by incubating the cells in the decidualization media for 48hrs. After decidualization, Dual Luciferase Reporter Assays (Promega) were started by incubating the cells for 15mins in 20 $\mu$ l of 1x passive lysis buffer. Luciferase and renilla expression were then measured using the Glomax multi+ detection system (Promega). Luciferase expression values were standardized by the renilla expression values and background expression values as determined by pGL3-Basic expression.

## **The rs2071473 C allele is derived in humans and segregating at intermediate to high frequencies across multiple human populations**

To reconstruct the evolutionary history of the T/C polymorphism we used a region spanning 50bp upstream and downstream of rs2071473 from hg19 (chr6:32814778-32814878) as a query sequence to BLAT search the chimpanzee (CHIMP2.1.4), gorilla (gorGor3.1), orangutan (PPYG2), gibbon, (Nleu1.0), rhesus monkey (MMUL\_1), hamadryas baboon (Pham\_1.0), olive baboon (Panu\_2.0), vervet monkey (ChlSab1.0), marmoset (C\_jacchus3.2.1), Bolivian squirrel monkey (SalBol1.0), tarsier (tarSyr1), mouse lemur (micMur1), and galago (OtoGar3) genomes. For all other non-human species we used the same 101bp region as a query for SRA-BLAST against high-throughput sequencing reads deposited in SRA. The top scoring 100 reads were assembled into contigs using the 'Map to reference' option in Geneious v6.1.2 and the human sequence as a reference. Sequences for the Altai Neanderthal, Denisovan, Ust-Ishim, and two aboriginal Australians were obtained from the 'Ancient Genome Browser' (<http://www.eva.mpg.de/neandertal/draft-neandertal-genome.html>). The frequency of the C/T allele across the Human Genome Diversity Project (HGDP) populations was obtained from the 'Geography of Genetic Variants Browser' (<http://popgen.uchicago.edu/ggv/>).

We inferred ancestral sequences of the 101bp region using the ancestral sequence reconstruction (ASR) module of the Datamonkey web-server (<http://www.datamonkey.org>) [33] which implement joint, marginal, and sampled reconstruction methods [34], the nucleotide alignment of the 101bp, the best fitting nucleotide substitution model (HKY85), a general discrete model of site-to-site rate variation with 3 rate classes, and the phylogeny shown in Fig 4A. All three ASR methods reconstructed the same sequence for the ancestral human sequence at 1.0 support.

## **rs2071473 has signatures of balancing in humans and diversifying selection in primates**

To infer if there was evidence for positive selection acting on the derived T allele we used an improved version of the EvoNC method [35] that has been modified into a branch-site model [36,37], and implemented in HyPhy v2.22 [37,38]. This method utilizes the MG94HKY85 nucleotide substitution model, which was also the best-fitting nucleotide substitution model for our target non-coding region and neutral rate proxy, and includes 10 replicate likelihood searches. Although this implementation of the EvoNC method that has been modified into a

branch-site model capable of identifying positively selected sites in a priori defined lineages using Naive Empirical Bayes (NEB) and Bayes Empirical Bayes (BEB), previous studies have shown that these methods have high type-I and type-II error rates. Therefore, we inferred evidence for without reference to NEB or BEB identified sites and instead relied on a significant likelihood ratio test between the null and alternate models. We analyzed an alignment of the 101bp region described above, the phylogeny shown in Fig 4A, synonymous sites from the flanking *HLA-DOB* and *TAP2* genes which were identified from the same primate species using the method described above.

## Results

### **rs2071473 is a multi-tissue eQTL for *TAP2*, *HLA-DOB*, and *HLA-DRB6***

We previously have shown that a T/C polymorphism at rs2071473 is an eQTL for *TAP2* in mid-secretory phase endometrium [15]. To replicate this observation in an independent cohort and in additional tissues, we tested if rs2071473 was correlated with *TAP2* expression using GTEx data. Similarly to our previous observation, we found that rs2071473 was an eQTL for *TAP2* in GTEx uterus samples ( $n=70$ ,  $\beta=-1.1$ ,  $P=9.1\times 10^{-11}$ ; **Fig 1A**) as well as 34 other tissues (**Fig 1B**); the largest effect size was observed in the uterus (**Fig 1B**). We also used GTEx data to identify other genes for which rs2071473 was an eQTL and found that it was an eQTL for *HLA-DOB* in 25 tissues ( $\beta=-0.27 - -0.91$ ,  $P=5.4\times 10^{-9} - 9.1\times 10^{-20}$ ; **Supplementary Table 1**) and for *HLA-DRB6* in four tissues ( $\beta=0.37 - 0.46$ ,  $P=6.7\times 10^{-6} - 2.1\times 10^{-8}$ ; **Supplementary Table 1**). However, rs2071473 was not identified as a uterine eQTL for *HLA-DOB* or *HLA-DRB6* because neither gene is expressed in GTEx uterine tissues.

### ***TAP2* is expressed by decidual stromal cells at the maternal-fetal interface**

Although *TAP2* is expressed in the uterus, the mid-secretory phase endometrium is a complex tissue composed of numerous cell-types including perivascular mesenchymal stem-like cells [19,39], which are the likely precursors of endometrial stromal fibroblasts (ESFs)[18], decidual stromal cells (DSCs)[17,18], luminal and glandular epithelial cells, endothelial cells lining blood vessels, uterine natural killer cells (uNK)[40], uterine macrophage (uMP)[41,42], multiple populations of T-cells [43-46], and dendritic cells [47,48], among many others. To determine which cell-types express *TAP2* we examined its localization in endometrial biopsies from the Human Protein Atlas immunohistochemistry collection. We found that *TAP2* staining

was localized primarily to the luminal and glandular epithelium and ESFs in non-pregnant endometrium (**Fig 2A**), was particularly intense in DSCs in pregnant endometrium (**Fig 2B**), and was absent from trophoblast cells (**Fig 2B/C**). Thus, *TAP2* is expressed by maternal cells particularly DSCs at the maternal-fetal interface.

Next we tracked the expression of *TAP2* in the endometrium across the menstrual cycle using previously generated microarray expression data [25]. We found that *TAP2* expression reached its peak during the early secretory phase of the menstrual cycle and rapidly decreased in the mid-secretory phase (**Fig 2D**), suggesting that down-regulation of *TAP2* is regulated by progesterone and associated with endometrial receptivity to implantation. To infer if *TAP2* expression in the endometrium is regulated by progesterone we took advantage of an existing gene expression dataset of mid-secretory phase endometrial biopsies from women not taking hormonal contraceptives (n=11), and women using either the progestin-based contraceptives depot medroxyprogesterone acetate (DMPA) or levonorgestrel intrauterine system (LNG-IUS) for at least 6 months [26]. Consistent with regulation by progesterone, we found that *TAP2* expression was significantly lower in the endometria of women taking DMPA ( $P=0.002$ ) or LNG-IUS ( $P=0.012$ ) compared to controls (**Fig 2E**).

To directly test if *TAP2* is regulated by progesterone, we examined its expression in RNA-Seq data from ESFs treated with control media or differentiated (decidualized) with cAMP/MPA into DSCs [31,32] and found that *TAP2* was down-regulated ~33% by cAMP/MPA treatment (**Fig 2F**). To test if these effects were mediated by the progesterone receptor (PGR), we used a previously published dataset to compare *TAP2* expression in DSCs treated with a PGR-specific siRNA or a non-targeted siRNA [27] and found that knockdown of PGR significantly up-regulated *TAP2* expression in DSCs ( $P=0.01$ ). Thus we conclude that *TAP2* is down-regulated by progesterone during the differentiation of ESFs into DSCs and in the endometrium during the period of endometrial receptivity to implantation.

### **The rs2071473 variant switches a repressor into an activator**

Our observations that rs2071473 is an eQTL for *TAP2* and that *TAP2* expression is down-regulated by progesterone suggests rs2071473 may be located within or linked to a progesterone responsive enhancer. To identify such a regulatory element we used previously ChIP-Seq data from DSCs for the transcription factors PGR [32,49,50] and NR2F2 (COUP-TFII)

[51], which regulate the transcriptional response to progesterone and immune genes, respectively, H3K27ac which marks active enhancers, H3K4me3 which marks active promoters [32], and DNase-Seq and FAIRE-Seq to identify regions of open chromatin [32]. We found that rs2071473 was located 260bp upstream of PGR and NR2F2 binding sites, within local DNase FAIRE peaks, and in a region of elevated H3K4me3 and H3K27ac signal (**Fig 3A**) suggesting this region is a progesterone responsive *cis*-regulatory element.

To test if this locus has regulatory potential we synthesized a 1000bp region spanning 50bp upstream of rs2071732 to the 3'-end of the PGR ChIP-Seq peak (**Fig 3A**) with either the reference C allele or the alternate T allele and cloned them into the pGL3-Basic luciferase reporter vector, which lacks both an endogenous promoter and enhancer. Next we transiently transfected either the pGL3Basic-rs2071732T or pGL3Basic-rs2071732C luciferase reporter along with the pRL-null internal control vector into ESFs and DSCs and quantified luciferase and renilla expression using a dual luciferase assay.

We found that luciferase expression was significantly lower in ESFs (Wilcoxon test  $P=1.75\times 10^{-11}$ ) and DSCs (Wilcoxon test  $P=2.87\times 10^{-9}$ ) transfected with the pGL3Basic-rs2071732T reporter compared to empty pGL3Basic vector controls (**Fig 3B**). In stark contrast, luciferase expression was significantly higher in ESFs (Wilcoxon test  $P=1.42\times 10^{-9}$ ) and DSCs (Wilcoxon test  $P=2.53\times 10^{-13}$ ) transfected with the pGL3Basic-rs2071732T reporter compared to controls (**Fig 3B**). The difference in luciferase expression between the pGL3Basic-rs2071732T and pGL3Basic-rs2071732C was also significant in ESFs (Wilcoxon test  $P=2.50\times 10^{-12}$ ) and DSCs (Wilcoxon test  $P=1.76\times 10^{-11}$ ). Luciferase expression was significantly induced upon differentiation of ESFs to DSCs by cAMP/MPA treatment in both the pGL3Basic-rs2071732T (Wilcoxon test  $P=0.02$ ) and pGL3Basic-rs2071732C (Wilcoxon test  $P=2.53\times 10^{-13}$ ) transfected cells (**Fig 3B**). Thus we conclude that the locus in which rs2071473 resides is a progesterone responsive *cis*-regulatory element and that the T/C polymorphism switches an enhancer into a repressor.

### **The rs2071473 C allele likely disrupts a DDIT3 binding site**

The T/C polymorphism at rs2071473 is several hundred base pairs away from the PGR and NR2F2 binding sites and is therefore unlikely to directly effect their binding (**Fig 3A**). However our luciferase assay results indicate that the T/C polymorphism has regulatory effects,

suggesting this polymorphism disrupts a binding site for a transcriptional repressor or creates a binding site transcriptional activator. To infer which of these scenarios was most likely we identified putative transcription factor binding sites in a 25bp window upstream and downstream of rs2071473 using ConSite [52] and JASPAR transcription factor binding site profiles [53]. We found that the T/C polymorphism occurs at an invariant T site in the DDIT3 motif (TGCAAT), which was predicted to abolish DDIT3 binding (**Fig 3A, inset**). Similarly, the T/C polymorphism was predicted by DeepSea [54], a deep learning-based algorithm that infers the effects of single nucleotide substitutions on chromatin features such as transcription factors binding, DNase I sensitivity, and histone marks, to generally have a negative effects on regulatory functions across multiple cell-types (**Fig 3C**).

While DDIT3 (also known as CHOP10 and GADD153) was initially characterized as a dominant negative inhibitor of CEBP family transcription factors [55], it can also function as a transcription factor [56,57] and is transcriptionally regulated the cAMP [58]. Indeed we found that CHOP10 expression was down-regulated by cAMP/MPA in our RNA-Seq data from ESFs (TPM=187.68) and DSCs (TPM=61.20). These data suggest that the T/C polymorphism may disrupt a DDIT3 binding site that mediates transcriptional repression of *TAP2*, unmasking a secondary enhancer function. To test this hypothesis we co-transfected ESFs and DSCs with a DDIT3 expression vector, the pRL-null internal control vector, and either the pGL3Basic-rs2071732T or pGL3Basic-rs2071732C luciferase reporter, and compared luciferase expression to control ESFs and DSCs. If DDIT3 mediates repression by binding the T allele, then co-transfection of DDIT3 with the pGL3Basic-rs2071732T reporter should augment repression whereas co-transfection with the pGL3Basic-rs2071732C reporter should be unaffected. Indeed, expression of DDIT3 significantly reduced luciferase expression from the pGL3Basic-rs2071732T reporter in ESFs (Wilcox test  $P=3.48 \times 10^{-10}$ ) and DSCs (Wilcox test  $P=1.591 \times 10^{-5}$ ) but had no effect on luciferase expression from the the pGL3Basic-rs2071732C reporter in either ESFs or DSCs ( $P > 0.21$ ; **Fig 3B**).

To test if this regulatory element is progesterone-responsive, we co-transfected ESFs and DSCs with a PGR rather than a DDIT3 expression vector and repeated the luciferase assays described above. Expression of PGR did not affect luciferase expression from the pGL3Basic-rs2071732T reporter in ESFs (Wilcox test  $P=0.67$ ) but did enhance repression in DSCs (Wilcox test  $P=9.56 \times 10^{-5}$ ; **Fig 3B**). Co-transfection of PGR elevated luciferase expression

from the pGL3Basic-rs2071732C reporter in both ESFs (Wilcox test  $P=2.82\times 10^{-8}$ ) and DSCs (Wilcox test  $P=2.53\times 10^{-13}$ ; **Fig 3B**). Finally we tested whether DDIT3 and PGR acted cooperatively or antagonistically by co-transfecting both the DDIT3 and PGR expression vectors with either the pGL3Basic-rs2071732T or pGL3Basic-rs2071732C reporters into ESFs and DSCs. Consistent with a weakly antagonistic functional interaction, luciferase expression in DDIT3 and PGR transfected ESFs and DSCs was intermediate between luciferase expression DDIT3 or PGR transfected cells (**Fig 3B**). These data suggest that the reference C allele likely disrupts a DDIT3 binding site, which unmasks a progesterone responsive enhancer.

### **The rs2071473 C allele is derived in humans and has evidence of positive selection**

To reconstruct the evolutionary history of the T/C polymorphism we identified a region spanning 50bp upstream and downstream of rs2071473 from 45 primates, including species from each the major primate lineages, multiple sub-species of African apes (Homininae), as well as modern and archaic (Altai Neanderthal and Denisova) humans. Next we used maximum likelihood methods to reconstruct ancestral sequences for this 101bp region. We found that the T allele was ancestral in primates and that the C variant was only found in modern human populations as well as the Altai Neanderthal genome (**Fig 4A**). Next we examined the frequency of these alleles across the Human Genome Diversity Project (HGDP) populations as well as two aboriginal Australians and found that the derived and ancestral alleles were segregating at intermediate to high frequencies in nearly all human populations (**Fig 4B**). These results indicate that the derived C variant at rs2071473 arose before the divergence of modern and archaic human lineages.

To test if the derived C allele may have been positively selected we used a branch-sites version of the EvoNC method [35-37]. In this analysis, the nucleotide substitution rate in noncoding regions ( $d_{nc}$ ) is compared with a neutral rate proxy from either introns or synonymous substitutions ( $d_s$ ) in nearby coding genes. The strength and direction of selection acting on non-coding regions is given by  $d_{nc}/d_s$  or  $\zeta$ , which is analogous to the  $d_N/d_S$  rate or  $\omega$ , with  $\zeta = 1$  indicating neutral evolution,  $\zeta < 1$  indicating negative (purifying) selection, and  $\zeta > 1$  indicating positive selection. We analyzed the 101bp region described above and synonymous sites from the flanking HLA-DOB and TAP2 genes, and fit three models to the data: 1) A null model that constrains  $\zeta \leq 1$  across all sites and lineages; 2) An alternate model that allows for  $\zeta \leq 1$  in foreground and background branches,  $\zeta \leq 1$  in background branches and  $\zeta > 1$  in the foreground

branch; and 3) An alternate model that allows for  $\zeta < 1$  in foreground and background branches,  $\zeta = 1$  in foreground and background branches,  $\zeta < 1$  in background and  $\zeta > 1$  in foreground branches, and  $\zeta = 1$  in background and  $\zeta > 1$  in foreground branches. The null model was rejected in favor of both alternate model 1 (alternate model 1 LRT=5.37;  $P=0.02$ ) and alternate model 2 (alternate model 2 LRT=5.38;  $P=0.02$ ), suggesting the T to C substitution may have been positively selected.

### **rs2071473 has signatures of balancing in humans and diversifying selection in primates**

Our observation that the C allele originated before the divergence of modern and archaic humans and is segregating at intermediate frequencies across modern human populations suggests that the ancestral and derived variants may be maintained by balancing selection. Previous studies have shown that balancing selection is common in the HLA region in which *TAP2* and rs2071473 are located [59-62]. DeGiorgio et al, for example, developed a model-based approach to identify signatures of ancient balancing selection and found that the *HLA-DOB* locus, in which rs2071473 is located, was an outlier (top 0.5% of all scores across the genome) in their scan for balancing selection [63]. Consistent with the action of long-term balancing selection, rs2071473 has essentially no differentiation between populations ( $F_{st} = 0 - 0.016$ ), and is located in region with a relative excess of common polymorphisms across CEU and YRI populations as measured by Tajima's D (1.16-2.07), Fay and Wu's H (-23.16 – -56.83), and Pi (86.41-107.71)(**Fig 5**).

To test if in the rs2071473 enhancer region evolve under positive diversifying selection across primates we used the sites version of the EvoNC method [35-37]. We fit three models to the alignment described above: 1) A null model that constrains  $\zeta \leq 1$  across all sites; 2) An alternate model that allows for categories of sites with  $\zeta \geq 1$  and  $\zeta < 1$ ; and 3) An alternate model that allows for categories of sites with  $\zeta < 1$ ,  $\zeta = 1$ , or  $\zeta > 1$ . We found that the null model was not rejected in favor of alternate model 1 (LRT=0;  $P=1$ ), however, alternative model 2 was a better fit to the data than either the null model LRT=11.76;  $P=0.019$ ) or alternative model 1 (LRT=11.78;  $P=0.0005$ ). These data indicate that including distinct rate classes for sites with  $\zeta < 1$  or  $\zeta = 1$  significantly improves the alternate model, and suggest that positive diversifying selection acts on sites in this regulatory element across primates.

## Discussion

The mechanisms that promote maternal tolerance of the antigenically distinct fetus are complex [64] and have been the subject of intense study since Medawar formulated the immunological paradox posed by pregnancy and proposed tolerance was achieved by physical separation of maternal and fetal tissues, maternal immunosuppression, and immaturity of fetal antigens [65]. It is now clear that rather than being a site of maternal immunosuppression [66], the maternal immune system in the endometrium plays an active role in establishing a permissive environment for implantation, placentation, and gestation. For example, maternal regulatory T cells (Tregs) [44,67], shifts in the Th1/Th2/Th17 balance [45], uterine natural killer cells [40,68], uterine dendritic cells [47], uterine macrophage [69], and signaling by DSCs [70-72] all contribute to establishing immunotolerance and even promote placental invasion into maternal tissues.

It has also become clear that the major histocompatibility complex (MHC) genes, which play an important role in the rejection of non-self tissues, contribute to maternal tolerance of the fetus [21]. Matching of HLA antigens between couples, for example, is associated with longer intervals from marriage to birth compared to couples not matching for HLA [73,74]; these longer intervals result from both higher miscarriage rates among couples matching for class I HLA-B antigens [14] and longer intervals to pregnancy among couples matching for class II HLA-DR antigens [13]. Similarly, the non-classical HLA class I genes HLA-F are associated with fecundability whereas overwhelming evidence indicates maternal and fetal HLA-G genotypes are associated with miscarriage, recurrent pregnancy loss, and preeclampsia [75-86]. Collectively these data implicate antigen presentation by MHC as one of the molecular mechanisms that underlie successful implantation, maternal immunotolerance, and the establishment and maintenance of pregnancy.

The ATP-binding cassette transporter TAP, a heterodimer composed of TAP1 and TAP2, translocates peptides from the cytosol to awaiting MHC class I molecules in the endoplasmic reticulum, which results in cell surface presentation of the trimeric MHC complex to immune cells such as T lymphocytes and natural killer cells [20]. Loss and reduced TAP expression leads to loss and reduced surface HLA expression [87-89], altered surface HLA repertoires [90], and the surface expression of distinct antigenic peptides that are recognized by cytotoxic T lymphocytes [91]. Our observation that TAP2 is highly expressed by DSCs at the

maternal-fetal interface and that *TAP2* expression levels are associated with fecundability suggests that changes in *TAP2* stoichiometry may alter MHC processing and thus interactions between DSCs and maternal immune cells. Indeed DSCs express numerous HLA class I molecules, including HLA-G and HLA-F [92,93], which are transcriptionally up-regulated by progesterone during decidualization [72].

While the connection between *TAP2* expression levels in DSCs and immune signaling are obvious, our observation that the ancestral and derived alleles of rs2071473 arose before the divergence of modern and archaic humans and has signatures of long-term balancing selection is unexpected. The HLA region has long been recognized to be under balancing selection [59,60,63,94,95]. These signals, however, are usually attributed to polymorphisms within the classical HLA class I genes rather regulatory regions (cf. [96]). *TAP2* and rs2071473 are also located near the distal end of the HLA region and bounded by regions of high recombination, including a recombination hotspot within *TAP2* [97], and in a LD block that includes few other HLA genes. These data suggest that the signal of balancing selection at rs2071473 is distinct from other signals of balancing selection in the HLA region, but it is difficult to disentangle these signals given the relatively strong linkage across the HLA region. Thus it is possible that the C/T polymorphism at rs2071473 is not itself under balancing selection and is linked to the balanced site.

If the target of balancing selection is rs2071473, what selective forces are acting to maintain the ancestral and derived alleles? Balancing selection is generally attributed to heterozygote advantage (overdominance), frequency dependent selection, or antagonistic pleiotropy [98], which are all probable evolutionary scenarios to explain maintenance of the ancestral and derived alleles of rs2071473. Intriguingly, GWA studies have found rs2071473 genotype is associated with ulcerative colitis [99], Crohn's disease [100], and sarcoidosis [101,102] in addition to fecundability. For example, the ancestral T allele is significantly associated with ulcerative colitis [99] and shorter time to pregnancy whereas the derived C allele is significantly associated with Crohn's disease [100] and longer time to pregnancy suggesting these alleles may be maintained antagonistic pleiotropy.

## Methods

**rs2071473 is a multi-tissue eQTL for *TAP2*, *HLA-DOB*, and *HLA-DRB6***

We replicated the association between the T/C polymorphism at rs2071473 and *TAP2* expression levels using GTEx Analysis Release V6 (dbGaP Accession phs000424.v6.p1) data for 35 tissues including the uterus [22,23]. We also used GTEx data to identify other genes for which rs2071473 was an eQTL. Briefly, we queried the GTEx database using the ‘Single tissue eQTLs search form’ for SNP rs2071473 (<http://www.gtexportal.org/home/eqtls/bySnp>).

### ***TAP2* is expressed by decidual stromal cells at the maternal-fetal interface**

To determine the cell-type localization of *TAP2* in the endometrium, we used data from the Human Protein Atlas immunohistochemistry collection ([www.proteinatlas.org](http://www.proteinatlas.org)) [24] for endometrium, placenta, and decidua. We examined the expression of *TAP2* in the endometrium across the menstrual cycle [25], in mid-secretory phase endometrial biopsies from women not taking hormonal contraceptives (n=11), and women using either the progestin-based contraceptives depot medroxyprogesterone acetate (DMPA) or levonorgestrel intrauterine system (LNG-IUS) for at least 6 months [26], and in DSCs treated with a PGR-specific siRNA or a non-targeted siRNA [27] using previously generated microarray expression data. These microarray datasets were analyzed with the GEO2R analysis package (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>), which implements the GEOquery [28] and limma R packages [29,30] from the Bioconductor project to quantify differential gene expression. We also examined *TAP2* expression in RNA-Seq data previously generated from ESFs treated with control media or differentiated (decidualized) with cAMP/MPA into DSCs [31,32].

### **Cell culture and luciferase assays**

#### Cell culture

Endometrial stromal fibroblasts (ATCC CRL-4003) immortalized with telomerase were maintained in phenol red free DMEM (Gibco) supplemented with 10% charcoal stripped fetal bovine serum (CSFBS; Gibco), 1x ITS (Gibco), 1% sodium pyruvate (Gibco), and 1% L-glutamine (Gibco). Decidualization was induced using DMEM with phenol red (Gibco), 2% CSFBS (Gibco), 1% sodium pyruvate (Gibco), 0.5mM 8-Br-cAMP (Sigma), and 1 $\mu$ M medroxyprogesterone acetate (Sigma).

#### Plasmid Transfection and Luciferase Assays

A 1000bp region spanning 50bp upstream of rs2071732 to the 3'-end of the PGR ChIP-Seq peak was cloned into the pGL3-Basic luciferase vector (Promega), once with the T allele

and once with the C allele (Genscript). A pGL3-Basic plasmid without the 1kb rs2071473 insert was used as a negative expression control. DDIT3 and PGR expression plasmids were also obtained from Genscript. Confluent ESFs in 96 well plates in 80 $\mu$ l of Opti-MEM (Gibco) were transfected with 100ng of the luciferase plasmid, 100ng of DDIT3 and/or PGR as needed, and 10ng of pRL-null with 0.1 $\mu$ l PLUS reagent (Invitrogen) and 0.25 $\mu$ l of Lipofectamine LTX (Invitrogen) in 20 $\mu$ l Opti-MEM. The cells incubated in the transfection mixture for 6hrs and the media was replaced with the phenol red free maintenance media overnight. Decidualization was then induced by incubating the cells in the decidualization media for 48hrs. After decidualization, Dual Luciferase Reporter Assays (Promega) were started by incubating the cells for 15mins in 20 $\mu$ l of 1x passive lysis buffer. Luciferase and renilla expression were then measured using the Glomax multi+ detection system (Promega). Luciferase expression values were standardized by the renilla expression values and background expression values as determined by pGL3-Basic expression.

### **The rs2071473 C allele is derived in humans and segregating at intermediate to high frequencies across multiple human populations**

To reconstruct the evolutionary history of the T/C polymorphism we used a region spanning 50bp upstream and downstream of rs2071473 from hg19 (chr6:32814778-32814878) as a query sequence to BLAT search the chimpanzee (CHIMP2.1.4), gorilla (gorGor3.1), orangutan (PPYG2), gibbon, (Nleu1.0), rhesus monkey (MMUL\_1), hamadryas baboon (Pham\_1.0), olive baboon (Panu\_2.0), vervet monkey (ChlSab1.0), marmoset (C\_jacchus3.2.1), Bolivian squirrel monkey (SalBol1.0), tarsier (tarSyr1), mouse lemur (micMur1), and galago (OtoGar3) genomes. For all other non-human species we used the same 101bp region as a query for SRA-BLAST against high-throughput sequencing reads deposited in SRA. The top scoring 100 reads were assembled into contigs using the 'Map to reference' option in Geneious v6.1.2 and the human sequence as a reference. Sequences for the Altai Neanderthal, Denisovan, Ust-Ishim, and two aboriginal Australians were obtained from the 'Ancient Genome Browser' (<http://www.eva.mpg.de/neandertal/draft-neandertal-genome.html>). The frequency of the C/T allele across the Human Genome Diversity Project (HGDP) populations was obtained from the 'Geography of Genetic Variants Browser' (<http://popgen.uchicago.edu/ggv/>).

We inferred ancestral sequences of the 101bp region using the ancestral sequence reconstruction (ASR) module of the Datamonkey web-server (<http://www.datamonkey.org>) [33] which implement joint, marginal, and sampled reconstruction methods [34], the nucleotide alignment of the 101bp, the best fitting nucleotide substitution model (HKY85), a general discrete model of site-to-site rate variation with 3 rate classes, and the phylogeny shown in Fig 4A. All three ASR methods reconstructed the same sequence for the ancestral human sequence at 1.0 support.

### **rs2071473 has signatures of balancing in humans and diversifying selection in primates**

To infer if there was evidence for positive selection acting on the derived T allele we used an improved version of the EvoNC method [35] that has been modified into a branch-site model [36,37], and implemented in HyPhy v2.22 [37,38]. This method utilizes the MG94HKY85 nucleotide substitution model, which was also the best-fitting nucleotide substitution model for our target non-coding region and neutral rate proxy, and includes 10 replicate likelihood searches. Although this implementation of the EvoNC method that has been modified into a branch-site model capable of identifying positively selected sites in a priori defined lineages using Naive Empirical Bayes (NEB) and Bayes Empirical Bayes (BEB), previous studies have shown that these methods have high type-I and type-II error rates. Therefore, we inferred evidence for without reference to NEB or BEB identified sites and instead relied on a significant likelihood ratio test between the null and alternate models. We analyzed an alignment of the 101bp region described above, the phylogeny shown in Fig 4A, synonymous sites from the flanking *HLA-DOB* and *TAP2* genes which were identified from the same primate species using the method described above.  $F_{st}$ , Tajima's D, and Fay and Wu's H data for CEU and YRI populations were obtained from the 1000 Genomes Selection Browser 1.0 [103].

### **Acknowledgments**

This work was funded by a University of Chicago new lab startup package, a Burroughs Wellcome Preterm Birth Initiative grant, and a March of Dimes Transdisciplinary center grant (V.J.L.). The authors thank C. Ober for comments on an earlier version of this manuscript.

## References

1. Kosova G, Abney M, Ober C. Heritability of reproductive fitness traits in a human population. *Proc Natl Acad Sci USA*. 2010;107: 1772–1778. doi:10.1073/pnas.0906196106
2. Christensen K, Kohler HP, Basso O, Olsen J. The correlation of fecundability among twins: evidence of a genetic effect on fertility? .... 2003.
3. Tropf FC, Verweij RM, van der Most PJ, Stulp G. Mega-analysis of 31,396 individuals from 6 countries uncovers strong gene-environment interaction for human fertility. *bioRxiv*. 2016.
4. Ruth KS, Beaumont RN, Tyrrell J, Jones SE, Tuke MA, Yaghootkar H, et al. Genetic evidence that lower circulating FSH levels lengthen menstrual cycle, increase age at menopause and impact female reproductive health. *Hum Reprod*. 2016;31: 473–481. doi:10.1093/humrep/dev318
5. Elks CE, Perry J, Sulem P, Chasman DI. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. *Nature*. 2010.
6. He C, Kraft P, Chen C, Buring JE, Paré G. Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. *Nature*. 2009.
7. Perry JRB, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature*. 2014;514: 92–97. doi:10.1038/nature13545
8. Stolk L, Perry JRB, Chasman DI, He C, Mangino M, Sulem P, et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. *Nat Genet*. 2012;44: 260–268. doi:10.1038/ng.1051
9. Chen CTL, Liu C-T, Chen GK, Andrews JS, Arnold AM, Dreyfus J, et al. Meta-analysis of loci associated with age at natural menopause in African-American women. *Hum Mol Genet*. 2014;23: 3327–3342. doi:10.1093/hmg/ddu041
10. Mbarek H, Steinberg S, Nyholt DR, Gordon SD, Miller MB, McRae AF, et al. Identification of Common Genetic Variants Influencing Spontaneous Dizygotic Twinning and Female Fertility. *Am J Hum Genet*. 2016;98: 898–908. doi:10.1016/j.ajhg.2016.03.008
11. Aschebrook-Kilfoy B, Argos M, Pierce BL, Tong L, Jasmine F, Roy S, et al. Genome-wide association study of parity in Bangladeshi women. *PLoS ONE*. 2015;10: e0118488. doi:10.1371/journal.pone.0118488
12. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. *Hum Reprod*. 2012;27: 594–608. doi:10.1093/humrep/der391

13. Ober C, Elias S, Kostyu DD, Hauck WW. Decreased fecundability in Hutterite couples sharing HLA-DR. *Am J Hum Genet.* 1992;50: 6–14.
14. Ober C, Hyslop T, Elias S, Weitkamp LR, Hauck WW. Human leukocyte antigen matching and fetal loss: results of a 10 year prospective study. *Hum Reprod.* 1998;13: 33–38.
15. Burrows CK, Kosova G, Herman C, Patterson K, Hartmann KE, Valez Edwards DR, et al. Expression Quantitative Trait Locus Mapping Studies in Mid-Secretory Phase Endometrial Cells Identifies HLA-F and TAP2 as Fecundability-Associated Genes. *PLoS Genet VL - IS - UR - SP - EP* . Public Library of Science M3 ; 2016.
16. Dimitriadis E, Sharkey AM, Tan YL. [REDIRECT] <http://www.biomedcentral.com/content/pdf/1477-7827-5-44.pdf>. *Reprod Biol ....* 2007.
17. Gellersen B, Brosens J. Cyclic AMP and progesterone receptor cross-talk in endometrium: a decidualizing affair. *J Endocrinology.* 2003;178: 357–372.
18. Gellersen B, Brosens IA, Brosens JJ. Decidualization of the human endometrium: mechanisms, functions, and clinical perspectives. *Semin Reprod Med.* 2007;25: 445–453. doi:10.1055/s-2007-991042
19. Murakami K, Lee YH, Lucas ES, Chan Y-W, Durairaj RP, Takeda S, et al. Decidualization induces a secretome switch in perivascular niche cells of the human endometrium. *Endocrinology.* 2014;155: 4542–4553. doi:10.1210/en.2014-1370
20. Karttunen JT, Lehner PJ, Gupta SS, Hewitt EW, Cresswell P. Distinct functions and cooperative interaction of the subunits of the transporter associated with antigen processing (TAP). *Proc Natl Acad Sci USA.* 2001;98: 7431–7436. doi:10.1073/pnas.121180198
21. Fernandez N, Cooper J, Sprinks M. A critical review of the role of the major histocompatibility complex in fertilization, preimplantation development and fetomaternal interactions. *Human Reproduction.* 1999.
22. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science.* 2015;348: 648–660. doi:10.1126/science.1262110
23. Melé M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, et al. Human genomics. The human transcriptome across tissues and individuals. *Science.* 2015;348: 660–665. doi:10.1126/science.aaa0355
24. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science.* 2015;347: 1260419. doi:10.1126/science.1260419
25. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and

- underlying biological processes in normo-ovulatory women. *Endocrinology*. 2006;147: 1097–1121. doi:10.1210/en.2005-1076
26. Goldfien GA, Barragan F, Chen J, Takeda M, Irwin JC, Perry J, et al. Progestin-Containing Contraceptives Alter Expression of Host Defense-Related Genes of the Endometrium and Cervix. *Reprod Sci*. 2015;22: 814–828. doi:10.1177/1933719114565035
  27. Pabona JMP, Simmen FA, Nikiforov MA, Zhuang D, Shankar K, Velarde MC, et al. Krüppel-like factor 9 and progesterone receptor coregulation of decidualizing endometrial stromal cells: implications for the pathogenesis of endometriosis. *J Clin Endocrinol Metab*. 2012;97: E376–92. doi:10.1210/jc.2011-2562
  28. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. *Bioinformatics*. 2007;23: 1846–1847. doi:10.1093/bioinformatics/btm254
  29. Smyth GK. Limma: linear models for microarray data. *Bioinformatics and computational biology solutions* .... 2005.
  30. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S. *Bioinformatics and computational biology solutions using R and Bioconductor*. 2006.
  31. Tamura I, Ohkawa Y, Sato T, Suyama M, Jozaki K, Okada M, et al. Genome-wide analysis of histone modifications in human endometrial stromal cells. *Mol Endocrinol*. 2014;28: 1656–1669. doi:10.1210/me.2014-1117
  32. Lynch VJ, Nnamani MC, Kapusta A, Brayer K, Plaza SL, Mazur EC, et al. Ancient Transposable Elements Transformed the Uterine Regulatory Landscape and Transcriptome during the Evolution of Mammalian Pregnancy. *Cell Rep*. 2015. doi:10.1016/j.celrep.2014.12.052
  33. Delpont W, Poon AFY, Frost SDW, Kosakovsky Pond SL. Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. *Bioinformatics*. 2010;26: 2455–2457. doi:10.1093/bioinformatics/btq429
  34. Pond S, Frost S. Not so different after all: a comparison of methods for detecting amino acid sites under selection. *Mol Biol Evol*. 2005.
  35. Wong WSW, Nielsen R. Detecting selection in noncoding regions of nucleotide sequences. *Genetics*. 2004;167: 949–958. doi:10.1534/genetics.102.010959
  36. Zhang J, Nielsen R, Yang Z. Evaluation of an improved branch-site likelihood method for detecting positive selection at the molecular level. *Mol Biol Evol*. 2005;22: 2472–2479. doi:10.1093/molbev/msi237
  37. Haygood R, Fedrigo O, Hanson B, Yokoyama KD. Promoter regions of many neural- and nutrition-related genes have experienced positive selection during human evolution. *Nature*. 2007.

38. Pond SLK, Frost SDW, Muse SV. HyPhy: hypothesis testing using phylogenies. *Bioinformatics*. 2005;21: 676–679. doi:10.1093/bioinformatics/bti079
39. Barragan F, Irwin JC, Balayan S, Erikson DW, Chen JC, Houshdaran S, et al. Human Endometrial Fibroblasts Derived from Mesenchymal Progenitors Inherit Progesterone Resistance and Acquire an Inflammatory Phenotype in the Endometrial Niche in Endometriosis. *Biol Reprod*. 2016. doi:10.1095/biolreprod.115.136010
40. Felker AM, Croy BA. Uterine natural killer cell partnerships in early mouse decidua basalis. *J Leukoc Biol*. 2016. doi:10.1189/jlb.1HI0515-226R
41. Svensson J, Jenmalm MC, Matussek A, Geffers R, Berg G, Ernerudh J. Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. *J Immunol*. 2011;187: 3671–3682. doi:10.4049/jimmunol.1100130
42. De M, Sanford T, Wood GW. Relationship between macrophage colony-stimulating factor production by uterine epithelial cells and accumulation and distribution of macrophages in the uterus of pregnant mice. *J Leukoc Biol*. 1993;53: 240–248.
43. Exley MA, Boyson JE. Protective role of regulatory decidual  $\gamma\delta$  T cells in pregnancy. *Clin Immunol*. 2011;141: 236–239. doi:10.1016/j.clim.2011.09.004
44. Erlebacher A. Mechanisms of T cell tolerance towards the allogeneic fetus. *Nat Rev Immunol*. 2013;13: 23–33. doi:10.1038/nri3361
45. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and Regulatory T-Cell Paradigm in Pregnancy. *Am J Reprod Immunol*. 2010;63: 601–610. doi:10.1111/j.1600-0897.2010.00852.x
46. Reinhard G, Noll A, Schlebusch H, Mallmann P, Ruecker AV. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes. *Biochem Biophys Res Commun*. 1998;245: 933–938. doi:10.1006/bbrc.1998.8549
47. Tagliani E, Erlebacher A. Dendritic cell function at the maternal-fetal interface. *Expert Rev Clin Immunol*. 2011;7: 593–602. doi:10.1586/eci.11.52
48. Dendritic cell entrapment within the pregnant uterus inhibits immune surveillance of the maternal/fetal interface in mice. 2009. doi:10.1172/JCI38714DS1
49. Mazur EC, Vasquez YM, Li X, Kommagani R, Jiang L, Chen R, et al. Progesterone receptor transcriptome and cistrome in decidualized human endometrial stromal cells. *Endocrinology*. 2015;156: 2239–2253. doi:10.1210/en.2014-1566
50. Kaya HS, Hantak AM, Stubbs LJ, Taylor RN, Bagchi IC, Bagchi MK. Roles of progesterone receptor A and B isoforms during human endometrial decidualization. *Mol Endocrinol*. 2015;29: 882–895. doi:10.1210/me.2014-1363
51. Li X, Large MJ, Creighton CJ, Lanz RB, Jeong J-W, Young SL, et al. COUP-TFII

- regulates human endometrial stromal genes involved in inflammation. *Mol Endocrinol.* 2013;27: 2041–2054. doi:10.1210/me.2013-1191
52. Sandelin A, Wasserman WW, Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. *Nucleic Acids Res.* 2004;32: W249–52. doi:10.1093/nar/gkh372
  53. Mathelier A, Fornes O, Arenillas DJ, Chen C. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. *Nucleic acids ....* 2015.
  54. Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based sequence model. *Nat Methods.* 2015;12: 931–934. doi:10.1038/nmeth.3547
  55. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. *Genes Dev.* 1992;6: 439–453.
  56. Jauhainen A, Thomsen C, Strömbom L, Grundevik P, Andersson C, Danielsson A, et al. Distinct cytoplasmic and nuclear functions of the stress induced protein DDIT3/CHOP/GADD153. *PLoS ONE.* 2012;7: e33208. doi:10.1371/journal.pone.0033208
  57. Gao H, Schwartz RC. C/EBPzeta (CHOP/Gadd153) is a negative regulator of LPS-induced IL-6 expression in B cells. *Mol Immunol.* 2009;47: 390–397. doi:10.1016/j.molimm.2009.09.002
  58. Pomerance M, Carapau D, Chantoux F, Mockey M, Correze C, Francon J, et al. CCAAT/enhancer-binding protein-homologous protein expression and transcriptional activity are regulated by 3',5'-cyclic adenosine monophosphate in thyroid cells. *Mol Endocrinol.* 2003;17: 2283–2294. doi:10.1210/me.2002-0400
  59. Hedrick PW, Thomson G. Evidence for balancing selection at HLA. *Genetics.* 1983.
  60. Bubb KL, Bovee D, Buckley D, Haugen E, Kibukawa M, Paddock M, et al. Scan of human genome reveals no new Loci under ancient balancing selection. *Genetics.* 2006;173: 2165–2177. doi:10.1534/genetics.106.055715
  61. Andrés AM, Hubisz MJ, Indap A, Torgerson DG, Degenhardt JD, Boyko AR, et al. Targets of balancing selection in the human genome. *Mol Biol Evol.* 2009;26: 2755–2764. doi:10.1093/molbev/msp190
  62. Cagliani R, Riva S, Pozzoli U, Fumagalli M, Comi GP, Bresolin N, et al. Balancing selection is common in the extended MHC region but most alleles with opposite risk profile for autoimmune diseases are neutrally evolving. *BMC Evol Biol.* 2011;11: 171. doi:10.1186/1471-2148-11-171
  63. DeGiorgio M, Lohmueller KE, Nielsen R. A model-based approach for identifying signatures of ancient balancing selection in genetic data. *PLoS Genet.* 2014;10:


e1004561. doi:10.1371/journal.pgen.1004561

64. Erlebacher A. Why isn't the fetus rejected? *Curr Opin Immunol.* 2001;13: 590–593.
65. Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. *Symp Soc Exp Biol.* 1953;7.
66. Moffett A, Loke YW. The immunological paradox of pregnancy: a reappraisal. *Placenta.* 2004;25: 1–8. doi:10.1016/S0143-4004(03)00167-X
67. Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? 2009.
68. González IT, Barrientos G, Freitag N, Otto T. Uterine NK cells are critical in shaping DC immunogenic functions compatible with pregnancy progression. *PLoS ONE.* 2012.
69. Nagamatsu T, Schust DJ. Review: The Immunomodulatory Roles of Macrophages at the Maternal–Fetal Interface. *Reproductive Sciences.* 2010.
70. Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A. Chemokine Gene Silencing in Decidual Stromal Cells Limits T Cell Access to the Maternal-Fetal Interface. *Science.* 2012;336: 1317–1321. doi:10.1126/science.1220030
71. Nagamatsu T, Schust DJ, Sugimoto J, Barrier BF. Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. *Hum Reprod.* 2009;24: 3160–3171. doi:10.1093/humrep/dep308
72. Komatsu T, Konishi I, Mandai M, Mori T, Hiai H, Fukumoto M. Expression of class I human leukocyte antigen (HLA) and beta2-microglobulin is associated with decidualization of human endometrial stromal cells. *Hum Reprod.* 1998;13: 2246–2251.
73. Ober C, Elias S, O'BRIEN E. HLA sharing and fertility in Hutterite couples: evidence for prenatal selection against compatible fetuses. ... of Reproductive .... 1988.
74. Ober CL, Martin AO, Simpson JL, Hauck WW, Amos DB, Kostyu DD, et al. Shared HLA antigens and reproductive performance among Hutterites. *Am J Hum Genet.* 1983;35: 994–1004.
75. Ober C, Aldrich CL, Chervoneva I, Billstrand C. Variation in the HLA-G promoter region influences miscarriage rates. *The American Journal of ....* 2003.
76. Tan CY, Ho J, Chong YS, Loganath A. Paternal contribution of HLA-G\* 0106 significantly increases risk for pre-eclampsia in multigravid pregnancies. *Molecular human ....* 2008.
77. Loisel DA, Billstrand C, Murray K. The maternal HLA-G 1597ΔC null mutation is associated with increased risk of pre-eclampsia and reduced HLA-G expression during pregnancy in African- .... *Molecular human ....* 2012.


78. O'Brien M, McCarthy T, Jenkins D, Paul P. Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease. *Cellular and Molecular ...* 2001.
79. Larsen MH, Hylenius S, Andersen A. The 3'-untranslated region of the HLA-G gene in relation to pre-eclampsia: revisited. *Tissue ...* 2010.
80. Moreau P, Contu L, Alba F, Lai S, Simoes R. HLA-G gene polymorphism in human placentas: possible association of G\* 0106 allele with preeclampsia and miscarriage. *Biology of ...* 2008.
81. Yie S, Li L, Xiao R, Librach CL. A single base-pair mutation in the 3'-untranslated region of HLA-G mRNA is associated with pre-eclampsia. *Mol Hum Reprod*. 2008.
82. Aldrich CL, Stephenson MD, Karrison T. HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. *Molecular human ...* 2001.
83. Pfeiffer KA, Fimmers R, Engels G. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. *Molecular human ...* 2001.
84. Suryanarayana V, Rao L, Kanakavalli M. Association between novel HLA-G genotypes and risk of recurrent miscarriages: a case-control study in a South Indian population. *Reproductive ...* 2008.
85. Fan W, Li S, Huang Z, Chen Q. Relationship between HLA-G polymorphism and susceptibility to recurrent miscarriage: a meta-analysis of non-family-based studies. *Journal of assisted reproduction and ...* 2014.
86. Hylenius S, Andersen A, Melbye M. Association between HLA-G genotype and risk of pre-eclampsia: a case-control study using family triads. *Molecular human ...* 2004.
87. Cromme FV, Airey J, Heemels MT. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. *The Journal of ...* 1994.
88. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. *Cell*. 1992;71: 1205-1214.
89. Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. *J Clin Invest*. 1999;103: 595-596. doi:10.1172/JCI6455
90. Oliveira CC, Querido B, Sluijter M, Derbinski J, van der Burg SH, van Hall T. Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires. *Eur J Immunol*. 2011;41: 3114-3124. doi:10.1002/eji.201141836
91. Durgeau A, Hage El F, Vergnon I, Validire P, de Montpréville V, Besse B, et al.

- Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. *J Immunol.* 2011;187: 5532–5539. doi:10.4049/jimmunol.1102060
92. Blanco O, Tirado I, Muñoz-Fernández R. Human decidual stromal cells express HLA-G Effects of cytokines and decidualization. *Human ....* 2008.
93. Reyes-Perdomo C, Torres K, Olivares EG, Silva P. Frontiers I Immunoregulatory activity of Decidual/Endometrial Stromal Cells in humans. *frontiersinorg*
94. Black FL, Hedrick PW. Strong balancing selection at HLA loci: evidence from segregation in South Amerindian families. *Proc Natl Acad Sci USA.* 1997;94: 12452–12456.
95. Markow T, Hedrick PW, Zuerlein K. HLA polymorphism in the Havasupai: evidence for balancing selection. *American journal of ....* 1993.
96. Tan Z, Shon AM, Ober C. Evidence of balancing selection at the HLA-G promoter region. *Hum Mol Genet.* 2005.
97. Jeffreys AJ, Ritchie A, Neumann R. High resolution analysis of haplotype diversity and meiotic crossover in the human TAP2 recombination hotspot. *Hum Mol Genet.* 2000;9: 725–733.
98. Carter AJR, Nguyen AQ. Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles. *BMC Med Genet.* 2011;12: 160. doi:10.1186/1471-2350-12-160
99. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet.* 2011;43: 246–252. doi:10.1038/ng.764
100. Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet.* 2010;42: 1118–1125. doi:10.1038/ng.717
101. Hofmann S, Fischer A, Nothnagel M, Jacobs G, Schmid B, Wittig M, et al. Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. *Eur Respir J.* 2013;41: 888–900. doi:10.1183/09031936.00033812
102. Fischer A, Ellinghaus D, Nutsua M, Hofmann S, Montgomery CG, Iannuzzi MC, et al. Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk. *Am J Respir Crit Care Med.* 2015;192: 727–736. doi:10.1164/rccm.201503-0418OC
103. Pybus M, Dall'Olio GM, Luisi P, Uzkudun M. 1000 Genomes Selection Browser 1.0: a genome browser dedicated to signatures of natural selection in modern humans. *Nucleic acids ....* 2013.


## Figures and Figure Legends




**Fig 1. Replication of the rs2071473 C/T polymorphism as an eQTL for TAP2.** (A) Uterine *TAP2* expression boxplots from GTEx data. Numbers below each boxplot are the number of individuals in each genotype. (B) Region association plot showing GTEx SNPs that are significant eQTLs for *TAP2* expression ( $-\log_{10}$  P-value, left y-axis), color-coded base on their LD with rs2071473 (purple diamond). Local recombination rates are shown on the right y-axis). (C) Gene-eQTL Visualizer plot showing significant eQTLs for *TAP2* (see inset key for ( $-\log_{10}$  P-value and effect size coding) across 39 GTEx tissues. Tissues are sorted by largest effect size top to bottom. Numbers in black ovals indicate sample sizes. The location of *TAP2* coding exons are shown with light blue shading, and the start site (TSS) and end site (TES) are indicated.




**Fig 2. *TAP2* is regulated by progesterone and is expressed by decidual stromal cells at the maternal-fetal interface.** (A) Immunohistochemistry staining showing *TAP2* expression in the non-pregnant endometrium. LE, luminal epithelium. GE, glandular epithelium. ESF, endometrial stromal fibroblast. (B) Immunohistochemistry staining showing *TAP2* expression in the pregnant endometrium (decidua). DSC, decidual stromal cell. Tr, trophoblast (placenta). (C) Immunohistochemistry staining showing *TAP2* expression in the placenta. Tr, trophoblast. (D) Relative expression of *TAP2* across the menstrual cycle. (E) Relative expression of *TAP2* in the endometrium of women using either the progestin-based contraceptives depot medroxyprogesterone acetate (MPA) or levonorgestrel intrauterine system (IUD). (F) Relative expression of *TAP2* in endometrial stromal fibroblasts treated with control media (ESFs) or differentiated into DSCs with cAMP/MPA for 48 hours. (G) Relative expression of *TAP2* in cAMP/MPA differentiated DSCs treated with a control siRNA or a PGR-specific siRNA (KD).



**Fig 3. The C/T polymorphism at rs2071473 is located within a progesterone responsive *cis*-regulatory element in decidual stromal cells. (A)** Location of rs2071473 with respect to histone modifications that characterize promoters (H3K4me4 ChIP-Seq), enhancers (H3K27ac ChIP-Seq), open chromatin (DNaseI-Seq, FAIRE-Seq), as well as PGR and NR2F2 ChIP-Seq binding sites. Inset, the rs2071473-C allele is predicted to disrupt a DDIT3 binding site. The 1kb region shown in light brown was cloned into the pGL3Basic luciferase reporter vector for functional characterization. **(B)** Luciferase assay results testing the regulatory potential of the T (pGL3Basic-rs2071473C) and C (pGL3Basic-rs2071473T) alleles in endometrial stromal fibroblasts treated with control media (ESFs) or differentiated into DSCs with cAMP/MPA for 48 hours. Data are shown as luciferase expression from the pGL3Basic-rs2071473C or pGL3Basic-rs2071473T reporter relative to renilla expression (pRL-null and empty vector (pGL3Basic) controls. +DDIT3, Relative luciferase expression from the pGL3Basic-rs2071473C or pGL3Basic-rs2071473T in ESFs and DSCs co-transfected with DDIT3. +PGR, Relative luciferase expression from the pGL3Basic-rs2071473C or pGL3Basic-rs2071473T in ESFs and DSCs co-transfected with PGR. +DDIT3 & PGR, Relative luciferase expression from the pGL3Basic-rs2071473C or pGL3Basic-rs2071473T in ESFs and DSCs co-transfected with DDIT3 and PGR. **(C)** DeepSea predicted effects (log<sub>2</sub> fold change) of rs2071473 on regulatory features across cell-types.



**Fig 4. Evolutionary history C/T polymorphism at rs2071473.** (A) rs2071473 genotype across extant and ancestral primates. Genotype in extant species is shown as circles next to species names at terminal branches. Genotype at internal nodes based on ancestral reconstruction is shown as circles. Purple, T. Green, C. P=0.02, indicates lineage identified as positive selected based on the branch-sites version of the EvoNC method. (B) Distribution of the T and C alleles of rs2071473 across HGDP populations.



**Fig 5. The rs2071473 C/T polymorphism has genetic signatures of balancing selection.** Fay and Wu's H statistic, Tajima's D, Fst, and nucleotide diversity (Pi) for HGDP CEU (green) and YRI (red) populations across the HLA-region of chromosome 6. The location of rs2071476 is shown with a vertical red line. Linkage disequilibrium across this region is shown the log odds score (LOD) with white diamonds indicate pairwise D' values less than 1 with no statistically significant evidence of LD (LOD < 2), light blue diamonds indicate high D' values (>0.99) with low statistical significance (LOD < 2), and light pink diamonds indicate high statistical significance (LOD >= 2) but the low D' (less than 0.5).